Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 90,180 shares at $55.95 ($5.1M) on 2025-01-27, disclosed to the SEC on 2025-01-31.
Scheduled sale ($5.1M) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.16 | 17,000 | $938K | 18.4% |
| 2 | $55.95 | 9,250 | $518K | 10.2% |
| 3 | $55.95 | 9,250 | $518K | 10.2% |
| 4 | $57.02 | 27,340 | $1.6M | 30.6% |
| 5 | $57.02 | 27,340 | $1.6M | 30.6% |
| Total | $56.45 avg | 90,180 |
| $5.1M |
| 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |